气候变化领域集成服务门户(CCPortal): Evolving epidemiology of poliovirus serotype 2 following withdrawal of the serotype 2 oral poliovirus vaccine

CCPortal

DOI	10.1126/science.aba1238
	Evolving epidemiology of poliovirus serotype 2 following withdrawal of the serotype 2 oral poliovirus vaccine
	Macklin G.R.; O’Reilly K.M.; Grassly N.C.; Edmunds W.J.; Mach O.; Santhana Gopala Krishnan R.; Voorman A.; Vertefeuille J.F.; Abdelwahab J.; Gumede N.; Goel A.; Sosler S.; Sever J.; Bandyopadhyay A.S.; Pallansch M.A.; Nandy R.; Mkanda P.; Diop O.M.; Sutter R.W.
发表日期	2020
ISSN	0036-8075
起始页码	401
结束页码	405
卷号	368 期号:6489
英文摘要	Although there have been no cases of serotype 2 wild poliovirus for more than 20 years, transmission of serotype 2 vaccine-derived poliovirus (VDPV2) and associated paralytic cases in several continents represent a threat to eradication. The withdrawal of the serotype 2 component of oral poliovirus vaccine (OPV2) was implemented in April 2016 to stop VDPV2 emergence and secure eradication of all serotype 2 poliovirus. Globally, children born after this date have limited immunity to prevent transmission. Using a statistical model, we estimated the emergence date and source of VDPV2s detected between May 2016 and November 2019. Outbreak response campaigns with monovalent OPV2 are the only available method to induce immunity to prevent transmission. Yet our analysis shows that using monovalent OPV2 is generating more paralytic VDPV2 outbreaks with the potential for establishing endemic transmission. A novel OPV2, for which two candidates are currently in clinical trials, is urgently required, together with a contingency strategy if this vaccine does not materialize or perform as anticipated. Copyright © 2020 The Authors,
关键词	poliomyelitis vaccine oral poliomyelitis vaccine disease transmission epidemiology immunity vaccine virus acute flaccid paralysis Article disease control disease eradication flaccid paralysis geography health care policy human Human poliovirus 2 immune deficiency immunization incidence intestinal mucosal immunity logistic regression analysis mucosal immunity priority journal public health campaign sanitation statistical model treatment withdrawal virus transmission epidemic global health immunology poliomyelitis Poliomyelitis virus procedures treatment withdrawal Poliovirus Disease Eradication Disease Outbreaks Global Health Humans Poliomyelitis Poliovirus Poliovirus Vaccine, Oral Withholding Treatment
语种	英语
来源机构	Science
文献类型	期刊论文
条目标识符	http://gcip.llas.ac.cn/handle/2XKMVOVA/133550
推荐引用方式 GB/T 7714	Macklin G.R.,O’Reilly K.M.,Grassly N.C.,et al. Evolving epidemiology of poliovirus serotype 2 following withdrawal of the serotype 2 oral poliovirus vaccine[J]. Science,2020,368(6489).
APA	Macklin G.R..,O’Reilly K.M..,Grassly N.C..,Edmunds W.J..,Mach O..,...&Sutter R.W..(2020).Evolving epidemiology of poliovirus serotype 2 following withdrawal of the serotype 2 oral poliovirus vaccine.,368(6489).
MLA	Macklin G.R.,et al."Evolving epidemiology of poliovirus serotype 2 following withdrawal of the serotype 2 oral poliovirus vaccine".368.6489(2020).